Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 4/20 | 0.51 |
| ▸ | RAD52 | P43351 | 4/20 | 0.51 |
| ▸ | GFER | P55789 | 3/20 | 0.51 |
| ▸ | KDM1A | O60341 | 10/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | RECQL | P46063 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | MITF | O75030 | 1/20 | 0.46 |
| ▸ | TOP2A | P11388 | 2/20 | 0.45 |
| ▸ | TOP2B | Q02880 | 2/20 | 0.45 |
| ▸ | GLA | P06280 | 2/20 | 0.45 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13529523 | 0.80 | TOP2B (0.71) | KMT2AMEN1GAAPOLBRAD52 | |
| SCHEMBL13530937 | 0.80 | KDM1A (0.70) | KMT2AMEN1GAAPOLBRAD52 | |
| SCHEMBL17154467 | 0.79 | KDM1A (0.58) | KMT2AMEN1GAAPOLBRAD52 | |
| SCHEMBL4939495 | 0.78 | MEN1 (0.67) | KMT2AMEN1GAAPOLBRAD52 | |
| SCHEMBL4939506 | 0.72 | KDM1A (0.75) | KMT2AMEN1GAAPOLBRAD52 | |
| SCHEMBL23630584 | 0.70 | KDM1A (0.78) | KMT2AMEN1GAAPOLBRAD52 | |
| SCHEMBL20856475 | 0.70 | KDM1A (0.60) | KMT2AMEN1GAAPOLBRAD52 | |
| SCHEMBL14116117 | 0.69 | KMT2A (0.97) | KMT2AMEN1GAAPOLBRAD52 | |
| SCHEMBL1870594 | 0.69 | KMT2A (0.63) | KMT2AMEN1GAAPOLBRAD52 | |
| SCHEMBL902770 | 0.69 | KDM1A (1.00) | KMT2AMEN1POLBRAD52GFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100022467-A1 | ANTI-CANCER PHOSPHONATE ANALOGS | BOOJAMRA CONSTANTINE G | 2010-01-28 | — | — | US | disclosed |
| US-7452901-B2 | Anti-cancer phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022467-A1 | ANTI-CANCER PHOSPHONATE ANALOGS | PIK3CA, PHOSPHO1, PTEN | KMT2A 2630/4885MEN1 914/4885GAA 1006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.